Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesQualitative or Semiquantitative ImmunoassaysCPT cpt-86386-nmp22-urine-assay-nuclear-matrix-protein-22
    Ask Trek AI about this page

    CPT 86386: NMP22 Urine Assay for Nuclear Matrix Protein 22

    CPT code 86386 describes a laboratory immunoassay for detection of elevated levels of nuclear matrix protein 22 (NMP22) in patient urine, a urine-based tumor marker test used to aid evaluation for urothelial carcinoma; service type: laboratory diagnostic test; typical site of service: clinical laboratory or hospital laboratory, with specimens collected in outpatient clinics or urology offices.

    For related coverage guidance, see recent payer policy updates: Allergen Subcutaneous Immunotherapy (SCIT), Allergy Testing, Including Selected Blood, Serum and Cellular Testing and Toxicity Testing Corporate Medical Policy, Allergy and Sensitivity Tests of Uncertain Efficacy.

    Customize your policy alerts

    Sign up for cpt 86386 policy alerts

    Get alerted when payer policies referencing 86386 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A typical patient is an adult presenting to an outpatient urology clinic with hematuria, urinary frequency, or a history of non–muscle invasive bladder cancer requiring surveillance. The clinician collects a urine specimen during the visit; the specimen is sent to the clinical laboratory where a lab analyst performs a protein-based immunoassay to detect elevated levels of nuclear matrix protein 22 (NMP22) in urine. Results are reported to the ordering urologist. Positive or elevated NMP22 may prompt cystoscopy, urine cytology, imaging, or enhanced surveillance; negative results may be documented and used alongside clinical assessment to determine next steps. Typical site of service is an outpatient clinic or hospital outpatient laboratory; testing may also occur in an independent clinical laboratory with specimen collection at the clinic or ambulatory surgical center.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    81002Urinalysis, by dipstick or reagent strip, non-automated, without microscopyCommon point-of-care screening test performed alongside NMP22 to document hematuria or infection
    81025Urine pregnancy test, by visual color comparison methodsPerformed in women of childbearing potential prior to certain diagnostic steps; may be part of initial urine panel
    88112Cytopathology, urine (exfoliative), other than urinary cytology, for malignant cells; limited examinationUrine cytology is often ordered in parallel with NMP22 for bladder cancer evaluation
    88342Immunohistochemistry or immunocytochemistry, per specimen; initial single or multiplex antibody stainUsed when cellular material from urine or biopsy requires additional marker testing after initial positive results
    52000Cystourethroscopy (separate procedure code for diagnostic cystoscopy)Direct visualization of the bladder often follows a positive NMP22 to identify lesions or confirm diagnosis
    81001Urinalysis, automated, with microscopyMore detailed urine analysis that may be ordered in conjunction with NMP22 testing

    Related Modifiers

    8 rows

    ModifierDescriptionWhen to Use
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…
    82Modifier 82 is appended to a surgical CPT code to indicate that an attending physician acted as an assistant because a qualified resident surgeon was unavailable. In teaching hospitals it documents…- When to use: Append modifier 82 in teaching-hospital settings to indicate a physician served as an assistant surgeon because a qualified resident surgeon was unavailable (includes situations where…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    208000000X
    207RC0000X
    207Q00000X
    363L00000X
    261QU0200X
    163WX0002X
    207WX0109X
    213ER0200X

    Related ICD-10-CM Codes

    26 rows

    ICD-10-CM CodeDescription
    C67.0Malignant neoplasm of trigone of bladder
    C67.1Malignant neoplasm of dome of bladder
    C67.2Malignant neoplasm of lateral wall of bladder
    C67.3Malignant neoplasm of anterior wall of bladder
    C67.4Malignant neoplasm of posterior wall of bladder
    C67.5Malignant neoplasm of bladder neck
    C67.6Malignant neoplasm of ureteric orifice
    C67.9Malignant neoplasm of bladder, unspecified
    D41.4Neoplasm of uncertain behavior of bladder
    N20.0Calculus of kidney

    Showing 1–10 of 26

    Related Payer Policy Updates

    Specialty: Allergy/Clinical Immunology1 / 3

    10 rows

    PolicyPayerEffective Date
    Allergen Subcutaneous Immunotherapy (SCIT)Providence Health Plan2026-11-01
    Allergy Testing, Including Selected Blood, Serum and Cellular Testing and Toxicity Testing Corporate Medical Policybcbsvermont2026-11-01
    Allergy and Sensitivity Tests of Uncertain Efficacyregence2026-10-01
    Allergy Testing and InjectionsUnitedHealthcare2026-10-01
    Allergy TestingProvidence Health Plan2026-10-01
    Diagnosis of Idiopathic Environmental IntoleranceOscar Health2026-10-01
    Allergen Testingblue cross blue shield - louisiana2026-09-15
    Allergen TestingBlue Cross Blue Shield - New Mexico2026-09-04
    Allergen Immunotherapymarylandphysicianscarempc2026-09-01
    ALLERGY TESTING / IMMUNOTHERAPYpriority_health_medicare2026-09-01

    Related Codes

    86803-QUALITATIVE-OR-SEMIQUANTITATIVE-IMMUNOASSAYS-HEPATITIS-C

    CPT 86803: Hepatitis C Antibody Immunoassay in Serum

    CPT-86000-FEBRILE-AGGLUTININS-SEROLOGIC-TEST

    CPT 86000: Febrile Agglutinins (Serologic Agglutination) Test

    CPT-86001-ALLERGEN-SPECIFIC-IGG-LABORATORY-TEST

    CPT 86001: Allergen-Specific IgG Assay, Technical Component

    CPT-86003-ALLERGEN-SPECIFIC-IGE-ASSAY-TECHNICAL

    CPT 86003: Allergen‑Specific IgE Assay Using Crude Allergen Extract

    CPT-86005-MULTI-ALLERGEN-IGE-SCREENING-QUALITATIVE

    CPT 86005: Multi-Allergen Allergen-Specific IgE Screening

    CPT-86008-ALLERGEN-COMPONENT-SPECIFIC-IGE-ASSAY

    CPT 86008: Allergen Component–Specific IgE Assay

    CPT-86015-ANTI-ACTIN-SMOOTH-MUSCLE-ANTIBODY-ASMA

    CPT 86015: Actin (Smooth Muscle) Antibody (ASMA) Immunoassay

    CPT-86021-LEUKOCYTE-ANTIBODY-IDENTIFICATION-LAB-TECHNICAL

    CPT 86021: Leukocyte Antibody Identification Laboratory Test

    CPT-86022-PLATELET-ANTIBODY-IDENTIFICATION-TECHNICAL-TEST

    CPT 86022: Platelet Antibody Detection and Identification

    CPT-86023-PLATELET-ASSOCIATED-IMMUNOGLOBULIN-DETECTION

    CPT 86023: Platelet-Associated Immunoglobulin Assay

    Showing 1–10 of 199

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.